Follow the Genscript Biotech Corporation stock price and the full directors' dealings record of the company, a publicly traded company based in Hong Kong. Shares trade on the HK market, under the oversight of HKEX. Operating in the Health Care sector, Genscript Biotech Corporation has logged 17 insider filings. Market capitalisation: €79.6bn. The latest transaction was disclosed on 7 September 2026 (Sale). Among the most active insiders: Zhu Li. Every trade is free.
17
Insider Decl.
n/a
Thresholds
n/a
5 ops.
Buy Volume
€2m
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Genscript Biotech Corporation Strong Buy (bullish), based on 7 analysts. Average price target: HK$29.16.
25Σ signal
Buys n/a€2m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,291 of 29,063 companies
33.2
score / 100
Value
35
Quality
31
FCF yld0.3%
Earn yld-0.7%
EV/EBITDA·
ROE-15%
Gross mgn58%
Net mgn-56%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
16,071 shares@ HK$12.25080.0003% mcap100.0% of flowShareXHKGHKEX:DA20260410E00415
17 of 17 declarations
Acerca de Genscript Biotech Corporation
Genscript Biotech Corporation es una empresa de biotecnología que ofrece servicios de investigación y productos para el desarrollo de fármacos. Cotiza en la Bolsa de Hong Kong.